| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 24.9 | 19.9 |
| Gross profit | 21.4 | 17.2 |
| Profit before tax | -6.8 | -8.2 |
| Net income | -6.8 | -8.2 |
| EPS (diluted, $ a share) | $-0.12 | $-0.16 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +25.2% |
|---|---|
| Gross margin | 85.9% |
| Operating margin | -24.6% |
10-Q filed with the SEC, NASDAQ: SGHT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Sight Sciences, Inc.: key numbers
- Share price
- $10.59Close, Nov 16
- Market cap
- $589M
- Shares outstanding
- 55.58MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Sight Sciences, Inc.
All →Sight Sciences Financial Results
Sight Sciences reported record third-quarter 2026 revenue of $24.9 million, a 25% increase year-over-year, driven by significant growth in its Interventional Dry Eye segment. The company improved its net loss to $6.8 million and raised its full-year 2026 revenue guidance to a range of $99.1 million to $101.1 million.
“We delivered another strong quarter with 25% total revenue growth, record IDE revenue, continued IG revenue growth, and a significant reduction in cash burn. These results demonstrate increasing adoption of our technologies, disciplined execution across our organization, and our growing impact on patients with glaucoma and dry eye disease.”
Paul Badawi, Co-Founder and CEO of Sight Sciences
Sight Sciences EVP, Operations & R&D Brenton Taylor Sells $26.5K of Stock
Brenton Taylor, EVP, Operations & R&D, sold 2,988 shares of Sight Sciences, Inc. at $8.85 a share, worth $26.5K in total on Oct 2, 2026. Shares held after the trade: 261,990 (-1.1%).
- Value
- $26.5K
- Shares
- 2,988
- Price
- $8.85
- Role
- EVP, Operations & R&D
- Holding change
- -1.1%
- Trade date
- Oct 2, 2026
Sight Sciences COO Alison Bauerlein Sells $224K of Stock
Alison Bauerlein, COO, sold 25,260 shares of Sight Sciences, Inc. at $8.85 a share, worth $224K in total on Oct 2, 2026. Shares held after the trade: 639,449 (-3.8%).
- Value
- $224K
- Shares
- 25,260
- Price
- $8.85
- Role
- COO
- Holding change
- -3.8%
- Trade date
- Oct 2, 2026
Sight Sciences CFO James Rodberg Sells $63.8K of Stock
James Rodberg, CFO, sold 7,208 shares of Sight Sciences, Inc. at $8.85 a share, worth $63.8K in total on Oct 2, 2026. Shares held after the trade: 216,829 (-3.2%).
- Value
- $63.8K
- Shares
- 7,208
- Price
- $8.85
- Role
- CFO
- Holding change
- -3.2%
- Trade date
- Oct 2, 2026
Sight Sciences CTO David Badawi Sells $70.6K of Stock
David Badawi, CTO, sold 7,797 shares of Sight Sciences, Inc. at $9.05 a share, worth $70.6K in total on Oct 1, 2026. Shares held after the trade: 1,975,075 (-0.4%).
- Value
- $70.6K
- Shares
- 7,797
- Price
- $9.05
- Role
- CTO
- Holding change
- -0.4%
- Trade date
- Oct 1, 2026
Sight Sciences President and CEO Paul Badawi Sells $268K of Stock
Paul Badawi, President and CEO, sold 29,653 shares of Sight Sciences, Inc. at $9.05 a share, worth $268K in total on Oct 1, 2026. Shares held after the trade: 6,092,819 (-0.5%).
- Value
- $268K
- Shares
- 29,653
- Price
- $9.05
- Role
- President and CEO
- Holding change
- -0.5%
- Trade date
- Oct 1, 2026